MRI Based Study to Assess Brain-gut Axis in Obesity (BGImaging)

June 23, 2022 updated by: University of Nottingham

Developing Magnetic Resonance Imaging Techniques to Explore the Brain-gut Axis to Food Intake in People With Obesity and Healthy Weight Participants

The mechanism of neural communication between the brain and gut in the regulation of food intake is complex and not fully understood. Magnetic Resonance Imaging (MRI) is a powerful non-invasive imaging tool that allows studying the function of the brain and gut. The aim of this study is to develop MRI methods to combine brain and gut imaging in a single MRI scan session. The developed techniques will then be used to assess the brain-gut axis to a high fat drink compared with iso-caloric/iso-viscous/iso-volumetric carbohydrate drink in people with obesity and healthy weight participants. The findings could provide a possible explanation for why some people are heavier than others.

Study Overview

Status

Recruiting

Conditions

Detailed Description

20 healthy weight participant (18 Kg/m2>BMI<30Kg/m2) and 20 age- and sex- matched peoples with obesity (BMI >30 Kg/m2) will be invited to a double-blinded two-way crossover MRI study, approximately 1 week apart, to assess the interplay between brain and gut to food intake.

Brain and gut MRI scans will be collected at fasted/baseline and at different time points postprandial for 120 mins using the 3T Ingenia Philips scanner. Brain measurements including resting state-fMRI, cerebral blood flow (CBF), and task-fMRI scans will be collected. During the task fMRI scan, images of high and low energy food pictures, and non-food control pictures will be presented. Food images are extensively used in fMRI studies to characterise the neural systems involved in processing the hedonic value of food as well as satiety and hunger signals. In addition to brain scans, sequences of gut scans will be collected to assess gastric volume, small bowel water content, and superior mesenteric artery (SMA) responses pre- and post-prandial. Blood samples will be collected to assess gut hormones (CCK, GLP1- PYY, ghrelin) insulin and glucose, triglycerides, free fatty acid levels at different timepoints. In addition, satiety and appetite scores will be collected using visual analogue scales. The total scan time including the fed and break times is around 3 hours.

Study Type

Interventional

Enrollment (Anticipated)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Aged 18-45, male and female (females will have the study days arranged during the early phase of the menstrual cycle).
  • Body mass index (BMI): normal weight participants ≥ 19 and ≤ 25 Kg/m2, and obese participants > 30 Kg/m2
  • Able to give voluntary written informed consent to participate in the study
  • Able to understand the requirements of the study
  • Apparently healthy: no medical conditions which might affect study measurements (judged by health questionnaire, and blood screening)

Exclusion Criteria:

  • Any reported history of neurological or gastrointestinal disorders
  • Any reported history of surgery that could affect gastrointestinal function (e.g. colectomy, small bowel resection)
  • Abnormal screening procedures including depression and eat restriction
  • Laboratory results that are clinically significant, including diabetes, dyslipidemia, pancreatitis, or untreated hypertension.
  • Contraindications for MRI scanning i.e. metallic implants, pacemakers, history of metallic foreign body in eye(s) and penetrating eye injury, assessed by standard MRI safety questionnaire.
  • Under medication (expect aspirin/paracetamol), antibiotic or prescribed probiotic treatment in the past 12 weeks.
  • Following a medically- or self-prescribed diet during the two weeks prior to the pre-study examination and until the end of the study.
  • Reported weight loss or gain ≥ 10 % of bodyweight during the six months period before the pre-study examination
  • Pregnancy or breastfeeding declared by candidate
  • Smoking
  • Left-handed assessed by handedness questionnaire. This is to control for brain's lateralisation effects (activation in one side of the brain) that may show variations between left and right handed participants.
  • Participation in another clinical or research study within the previous 3 months of the study
  • Cannot lie flat or exceeding the scanner bed weight limit of 250 kg.
  • Poor understanding of the spoken and/or written English language

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: Control group
Healthy weight group ( same age and sex)
300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)
ACTIVE_COMPARATOR: Obese group
300 mL of a 22% high fat emulsion (Rapeseed oil, water, emulsifier)
300 mL of isocaloric, iso-volumetric and iso-viscous carbohydrate drink (maltodextrin)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in appetite- and satiety-related brain responses between drinks ( Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Blood oxygen level-dependent (BOLD) responses to high-calorie, low-calorie and non-food images
From baseline to up to 2 hours after ingesting the drinks
Changes in Cerebral blood flow between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Cerebral blood flow differences
From baseline to up to 2 hours after ingesting the drinks
Changes resting state brain networks between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Alterations in functional brain connectivity/networks in brain regions involved in homeostatic and hedonic brain circuits.
From baseline to up to 2 hours after ingesting the drinks
Changes in gastric volume between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Area Under the Curve of post-prandial gastric volumes, measured by MRI
From baseline to up to 2 hours after ingesting the drinks
Correlations between gut and brain responses to assess alterations in brain-gut axis between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Exploratory correlations between brain and gut responses
From baseline to up to 2 hours after ingesting the drinks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in small bowel water content between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Area Under the Curve of post-prandial small bowel water content, measured by MRI, up to 2h (AUC2h) postprandially
From baseline to up to 2 hours after ingesting the drinks
Changes in satiety and appetite regulators between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Area Under the Curve of post-prandial serum gut hormone (CCK, GLP-1, PYY, Ghrelin), insulin, free fatty acid, glucose, and triglyceride concentrations
From baseline to up to 2 hours after ingesting the drinks
Changes in satiety and appetite score (VAS) between drinks (Fat drink VS Carbohydrate drink) and across groups (Healthy weight VS Obese)
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Area Under the Curve for appetite (Fullness, Hunger, Prospective food consumption) post prandial 100 mm VAS scores AUC2h
From baseline to up to 2 hours after ingesting the drinks
Correlations between blood, brain and gut and satiety date
Time Frame: From baseline to up to 2 hours after ingesting the drinks
Exploratory correlations between blood, brain and gut responses and satiety data
From baseline to up to 2 hours after ingesting the drinks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sally Eldeghaidy, PhD, University of Nottingham

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 28, 2022

Primary Completion (ANTICIPATED)

April 1, 2023

Study Completion (ANTICIPATED)

December 30, 2023

Study Registration Dates

First Submitted

April 8, 2022

First Submitted That Met QC Criteria

June 23, 2022

First Posted (ACTUAL)

June 29, 2022

Study Record Updates

Last Update Posted (ACTUAL)

June 29, 2022

Last Update Submitted That Met QC Criteria

June 23, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

will be available upon reasonable request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Nutritional Drink A

3
Subscribe